Lau, J., Bloch, P., Schffer, L., Pettersson, I., Spetzler, J., Kofoed, J.,
Our guidance offers patients a one-stop shop for our up-to-date advice on how to use these powerful medicines safely
Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes
Studies also suggest it supports longer-term use compared to phentermine, which has a limited treatment duration
Mild allergic reactions do not require any change per say
It occurs when the force of blood against the walls of the arteries is consistently too high